Lin Cang Shi

People with end stage kidney disease ESKD who require dialysis face a much higher risk of cardiovascular disease compared to the general population, with cardiac issues causing 58% of deaths in this group. However, while aspirin is known to reduce cardiovascular problems in the general population, there is limited evidence about its effects in dialysis patients. The ASPIrin to Reduce Event in Dialysis ASPIRED trial aims to study whether taking low-dose aspirin can safely improve cardiovascular outcomes in people with ESKD receiving dialysis. This study is a multi-center, double-blind, randomized controlled trial that will compare daily low-dose aspirin 100 mg to a placebo pill in patients undergoing dialysis. The trial uses an existing dialysis registry platform to screen, recruit, and collect data during routine clinical care, minimizing participant burden and study costs. Randomization is managed through a secure web-based system, and follow-up visits occur every six months as part of regular clinic visits. The trial is expected to last approximately five years and includes oversight by an independent safety and monitoring board. Participants will be involved in regular six-monthly clinic visits where their health will be monitored as part of their usual dialysis care. Researchers will track the occurrence of major cardiovascular events, including heart attacks, strokes, vascular complications, and deaths, throughout the study period. Data will be collected from routine clinical procedures and the dialysis registry to evaluate outcomes. Safety and efficacy will be closely monitored, and the study will follow participants for up to five years to assess the long-term effects of aspirin use in this population.

Researchers are evaluating an integrated child eye health service model in rural China to improve eye care for children and adolescents aged 3 to 18 years. This study aims to assess how well this county-based model works in real-world settings by looking at eye health screening coverage, correction of refractive errors, referrals after screening, and access disparities across different local levels such as county, township, village, and schools. The study focuses on common issues like myopia and amblyopia, which can affect childrens development if untreated. The study involves annual standardized eye health screenings conducted in schools under routine field conditions. These screenings include visual acuity tests, intraocular pressure measurements, and assessments for conditions like strabismus and amblyopia using various tools including a smartphone-based Digital Ruler of Strabismus. The service model also includes establishing referral systems and strengthening eye care capacity at county hospitals. The study is planned to run with data collected yearly over three years. Participants will undergo yearly eye examinations and screenings, with data collected on coverage rates, refractive error correction, screening detection rates, and referral outcomes. Researchers will monitor these clinical outcomes and track trends in access to eye care services. The study will also observe long-term effects on the management of pediatric eye diseases and visual function improvement. Participation includes informed consent and assent for older children, with a focus on sustaining eye health services and promoting equitable access in rural areas.

Researchers are evaluating the effects of a culturally adapted low glycemic index-high fiber LGI-HF diet on women with polycystic ovary syndrome PCOS living in remote areas of Yunnan Province. The study aims to observe changes in insulin resistance, androgen levels, and menstrual regularity over a 6-month period. This nutritional approach is designed to suit high-carbohydrate diets common in the area and balance feasibility with adherence, providing practical guidance for long-term PCOS management in resource-limited settings. The intervention includes a 24-week adaptive LGI-HF diet tailored for women with PCOS. Participants will follow the diet while maintaining their usual physical activity levels. Assessments will be conducted at the start, mid-point 12 weeks, and end 24 weeks of the intervention to evaluate metabolic and reproductive effects. During the study, participants will undergo evaluations including insulin resistance measurement using HOMA-IR at 12 weeks, fasting glucose and insulin tests, a six-hormone panel, and pelvic ultrasonography. The study monitors adherence to the diet and documents any changes in physical activity or medication use. Participants will be involved for at least 6 months, with safety and outcome measures carefully tracked throughout the period.